11.900
+0.120
+(1.02%)
At close: 4:08:07 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,294,585
6,294,585
3,744,952
913,788
2,348,113
Cost of Revenue
1,308,821
1,308,821
898,878
430,089
351,547
Gross Profit
4,985,764
4,985,764
2,846,074
483,699
1,996,566
Operating Expense
2,108,166
2,108,166
1,667,951
924,528
1,553,729
Operating Income
2,877,598
2,877,598
1,178,123
-440,829
442,837
Net Non Operating Interest Income Expense
-169,623
-169,623
-274,907
-232,461
-219,219
Pretax Income
2,126,771
2,126,771
39,422
-667,184
1,010,434
Tax Provision
270,945
270,945
-9,817
-79,460
173,023
Net Income Common Stockholders
1,992,624
1,992,624
76,603
-587,649
839,455
Average Dilution Earnings
--
--
--
--
-249,242
Diluted NI Available to Com Stockholders
1,992,624
1,992,624
76,603
-587,649
590,213
Basic EPS
2.26
2.26
0.09
-0.67
0.95
Diluted EPS
2.26
2.26
0.09
-0.67
0.53
Basic Average Shares
879,967.700
879,967.700
879,967.700
879,967.700
881,471.332
Diluted Average Shares
879,967.700
879,967.700
879,967.700
879,967.700
1,105,757.046
Total Operating Income as Reported
2,354,198
2,354,198
321,068
-423,377
1,254,640
Total Expenses
3,416,987
3,416,987
2,566,829
1,354,617
1,905,276
Net Income from Continuing & Discontinued Operation
1,992,624
1,992,624
76,603
-587,649
839,455
Normalized Income
2,472,911.477
2,472,911.477
619,399.500
-549,632.775
523,294.916
Interest Income
57,775
57,775
6,739
11,346
24,987
Interest Expense
227,398
227,398
281,646
243,807
244,206
Net Interest Income
-169,623
-169,623
-274,907
-232,461
-219,219
EBIT
2,354,169
2,354,169
321,068
-423,377
1,254,640
EBITDA
2,745,443
2,745,443
698,425
-163,561
1,377,366
Reconciled Cost of Revenue
1,308,821
1,308,821
898,878
430,089
351,547
Reconciled Depreciation
391,274
391,274
377,357
259,816
122,726
Net Income from Continuing Operation Net Minority Interest
1,992,624
1,992,624
76,603
-587,649
839,455
Total Unusual Items Excluding Goodwill
-550,408
-550,408
-622,534
-43,156
381,484
Total Unusual Items
-550,408
-550,408
-546,638
-43,156
381,484
Normalized EBITDA
3,295,851
3,295,851
1,245,063
-120,405
995,882
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-70,120.523
-70,120.523
-155,633.500
-5,139.775
65,323.916
12/31/2020 - 12/29/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2186.HK Luye Pharma Group Ltd.
1.910
+5.52%
067290.KQ JW Shinyak Corporation
1,596.00
-0.56%
3839.HK Chia Tai Enterprises International Limited
1.680
0.00%
0719.HK SHANDONG XINHUA
5.440
+0.37%
1513.HK LIVZON PHARMA
25.850
+0.58%
1061.HK ESSEX BIO-TECH
4.090
-0.49%
T14.SI Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
2.1500
+0.94%
2633.HK Jacobson Pharma Corporation Limited
1.220
0.00%
0013.HK HUTCHMED
22.100
+1.38%
2196.HK Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13.980
+1.16%